Company Description

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, focuses on delivering therapies to treat autoimmune diseases with unmet medical needs in the United States.

It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases.

It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc.

Country	Canada
Founded	1993
IPO Date	Jan 26, 1999
Industry	Biotechnology
Sector	Healthcare
Employees	130
CEO	Peter Greenleaf

Contact Details

Address: #140, 14315 – 118 Avenue Edmonton, AB T5L 4S6 Canada
Phone	250-744-2487
Website	auriniapharma.com

Stock Details

Ticker Symbol	AUPH
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001600620
CUSIP Number	05156V102
ISIN Number	CA05156V1022
Employer ID	98-1231763
SIC Code	2834

Key Executives

Name	Position
Peter S. Greenleaf M.B.A.	Chief Executive Officer and Director
Joseph M. Miller CPA	Chief Financial Officer
Matthew Maxwell Donley M.B.A.	Chief Operations Officer
Stephen P. Robertson	Executive Vice President of General Counsel
Dr. Gregory F. Keenan M.D.	Chief Medical Officer
Dr. Premchandran Ramiya Ph.D.	Senior Vice President of Manufacturing and Supply Chain

Latest SEC Filings

Date	Type	Title
Mar 4, 2025	SCHEDULE 13D/A	Filing
Feb 27, 2025	10-K	Annual Report
Feb 27, 2025	8-K	Current Report
Feb 14, 2025	SCHEDULE 13G/A	Filing
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024	10-Q	Quarterly Report
Nov 7, 2024	8-K	Current Report
Sep 12, 2024	SC 13D	General statement of acquisition of beneficial ownership
Sep 12, 2024	8-K	Current Report
Aug 1, 2024	10-Q	Quarterly Report

View All SEC Filings